The Laryngoscope · 2012 · 85 citations · 16 references
MedicineOncologyRadiologyOncologic Nuclear MedicineSurgical OncologyTumor PathologyLocal RecurrenceNeck ImagingRadiation TherapyRecurrence MonitoringRecurrence SurveillanceSquamous Cell Carcinoma18F-fluorodeoxyglucose Imaging18F-fluorodeoxyglucose Positron Emission TomographyDefinitive Concurrent ChemoradiationFluorine-18 Fluorodeoxyglucose Positron Emission TomographyHistopathologic ExaminationHistopathologic InterpretationImaging Of Tumor RecurrenceRadiographic Recurrence
OBJECTIVES/HYPOTHESIS: To estimate the distribution of head and neck squamous cell carcinoma (HNSCC) recurrence after definitive chemoradiation therapy (CRT) among patients who underwent 18F-fluorodeoxyglucose positron-emission tomography and computed tomography (PET/CT) surveillance. STUDY DESIGN: Retrospective review. METHODS: HNSCC patients who underwent definitive CRT from 2001 to 2008 were evaluated for recurrence with serial PET/CT. Patients were excluded if they were previously treated for recurrent disease, were treated with surgery as the primary therapeutic modality, or had inadequate clinical follow-up. Recurrence was defined by histopathologic evidence of tumor. RESULTS: Three hundred eighty-eight patients were studied. Patients in whom recurrence was not detected were followed clinically and radiographically for a median of 27 months. Tumor recurrence was detected in 110 patients. For 37 patients, recurrence was heralded by clinical signs. Among the 73 asymptomatic patients who had a confirmed recurrence, disease was detected by PET/CT between 2 and 43 months, median of 6 months. Forty-five percent of observed asymptomatic recurrences were detected during the first 6 months of surveillance (95% confidence interval [CI], 34%-57%), 79% within the first 12 months (95% CI, 68%-88%), 95% within the first 24 months (95% CI, 87%-98%), and 100% within the first 48 months (95% CI, 95%-100%). CONCLUSIONS: Among HNSCC patients followed with PET/CT surveillance, 95% of observed asymptomatic recurrences were detected within 24 months after completing CRT. For patients without clinical signs of recurrence, routine PET/CT surveillance beyond the first 24 months may be of limited value and may not be cost effective.
16
Global Cancer Statistics, 2002
Donald Maxwell Parkin, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2005 · 18.4K citations · Full text
Ahmedin Jemal, Rebecca L. Siegel, Jiaquan Xu et al. · CA A Cancer Journal for Clinicians · 2010 · 12.6K citations · Full text
Recent Advances in Head and Neck Cancer
Robert I. Haddad, Dong M. Shin · New England Journal of Medicine · 2008 · 926 citations
Medicine, Cancer Biology, Oncology +13
K. Kian Ang, Andy Trotti, Adam S. Garden et al. · International Journal of Radiation Oncology*Biology*Physics · 2001 · 633 citations · Full text